Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD
暂无分享,去创建一个
[1] M. Cosio,et al. Blood Eosinophilia Neither Reflects Tissue Eosinophils nor Worsens Clinical Outcomes in Chronic Obstructive Pulmonary Disease. , 2017, American journal of respiratory and critical care medicine.
[2] J. Soriano,et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD , 2017, European Respiratory Journal.
[3] E. Wouters,et al. Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts. , 2017, American journal of respiratory and critical care medicine.
[4] J. Wedzicha,et al. Blood and sputum eosinophils in COPD; relationship with bacterial load , 2017, Respiratory Research.
[5] J. Wedzicha,et al. Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial , 2017, American journal of respiratory and critical care medicine.
[6] B. Nordestgaard,et al. Association of Blood Eosinophil and Blood Neutrophil Counts with Asthma Exacerbations in the Copenhagen General Population Study. , 2017, Clinical chemistry.
[7] A. Vanasse,et al. Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions , 2017, Chest.
[8] I. Pavord,et al. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. , 2016, The Lancet. Respiratory medicine.
[9] Sally J. Singh,et al. Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. , 2016, Chest.
[10] P. Jones,et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD , 2016, International journal of chronic obstructive pulmonary disease.
[11] J. Wedzicha,et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. , 2016, The New England journal of medicine.
[12] B. Nordestgaard,et al. Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. , 2016, American journal of respiratory and critical care medicine.
[13] B. Nordestgaard,et al. Blood Eosinophils and Exacerbations in COPD: the Copenhagen General Population Study. , 2015 .
[14] I. Pavord,et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD , 2015, Thorax.
[15] S. Gungor,et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia , 2015, International journal of chronic obstructive pulmonary disease.
[16] J. Wedzicha,et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.
[17] F. Blasi,et al. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease , 2015, Thorax.
[18] B. Nordestgaard,et al. Characteristics and Prognosis of Never-Smokers and Smokers with Asthma in the Copenhagen General Population Study. A Prospective Cohort Study. , 2015, American journal of respiratory and critical care medicine.
[19] I. Pavord,et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. , 2015, The Lancet. Respiratory medicine.
[20] M. Woodhead,et al. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance , 2014, BMJ : British Medical Journal.
[21] Dave Singh,et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics , 2014, European Respiratory Journal.
[22] B. Nordestgaard,et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. , 2013, JAMA.
[23] F. Martinez,et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.
[24] B. Nordestgaard,et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.
[25] John Steer,et al. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease , 2012, Thorax.
[26] J. Wedzicha,et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. , 2012, Respiratory medicine.
[27] Christopher E Brightling,et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.
[28] S. Cole,et al. Overadjustment Bias and Unnecessary Adjustment in Epidemiologic Studies , 2009, Epidemiology.
[29] P. Jones,et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.
[30] David J Murphy,et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2008, JAMA.
[31] A. Torres,et al. New evidence of risk factors for community-acquired pneumonia: a population-based study , 2008, European Respiratory Journal.
[32] Susanna Navarro,et al. Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. , 2008, Biochemistry.
[33] T. Lasserson,et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.
[34] F. Maltais,et al. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment , 2006, European Respiratory Journal.
[35] I. Jónsdóttir,et al. Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response. , 2005, The Journal of allergy and clinical immunology.
[36] D. Postma,et al. Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. , 1999, American journal of respiratory and critical care medicine.
[37] J. Vestbo,et al. Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. , 1995, The European respiratory journal.
[38] C. McCall,et al. Eosinopenia of acute infection: Production of eosinopenia by chemotactic factors of acute inflammation. , 1980, The Journal of clinical investigation.